Appl. No. 10/817,506 Attorney Docket No. 89188.0060 Amdt. Dated August 15, 2007 Customer No.: 26021

Reply to Office Action of February 21, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-2. (Canceled)
- (Currently amended) The A method of elaim-2 generating regulatory cells comprising:

incubating one or more proteins comprising a cytolethal distending toxin (cdt), a leukotoxin (ltx) and/or a heat shock protein with blood cells for a time sufficient to induce differentiation, selective enrichment, and/or promoting proliferation of regulatory T cells, wherein said proteins are secreted from at least one pathogenic organism, wherein said pathogenic organism that secretes leukotoxin is Actinobacillus actinomycetemcomitans, Mannheimia (Pasteurella) haemolytica, or Fusobacterium necrophorum.

 (Currently amended) The A method of claim-2 generating regulatory cells comprising:

incubating one or more proteins comprising a cytolethal distending toxin (cdt), a leukotoxin (ltx) and/or a heat shock protein with blood cells for a time sufficient to induce differentiation, selective enrichment, and/or promoting proliferation of regulatory T cells, wherein said proteins are secreted from at least one pathogenic organism, wherein said pathogenic organism that secretes a cytolethal distending toxin is Actinobacillus actinomycetemcomitans, Escherichia coli Shigella dysentarie, Haemophilus ducreyi, Campylobacter upsaliensis, Campylobacter jejuni Helicobacter hepaticus, and Salmonella. enterica serovar Typhi genome.

Appl. No. 10/817,506 Attorney Docket No. 89188,0060 Amdt. Dated August 15, 2007 Customer No.: 26021

Reply to Office Action of February 21, 2007

 (Currently amended) The method of claim [[1]] 3, wherein said proteins are in a crude extract.

- 6. (Currently amended) The method of claim [[1]] 3, wherein said proteins are in a purified form.
- 7. (Currently amended) The A method of elaim-1 generating regulatory cells comprising:

incubating one or more proteins comprising a cytolethal distending toxin (cdt), a leukotoxin (ltx) and/or a heat shock protein with blood cells for a time sufficient to induce differentiation, selective enrichment, and/or promoting proliferation of regulatory T cells, wherein said proteins are expressed from at least one expression plasmid.

8. (Currently amended) The A method of elaim-1 generating regulatory cells comprising;

incubating one or more proteins comprising a cytolethal distending toxin (cdt), a leukotoxin (ltx) and/or a heat shock protein with blood cells for a time sufficient to induce differentiation, selective enrichment, and/or promoting proliferation of regulatory T cells, wherein said heat shock gene is GroEL.

(Currently amended) The A method of claim-1 generating regulatory cells comprising:

incubating one or more proteins comprising a cytolethal distending toxin (cdt), a leukotoxin (ltx) and/or a heat shock protein with blood cells for a time sufficient to induce differentiation, selective enrichment, and/or promoting

Appl. No. 10/817,506

Amdt. Dated August 15, 2007

idt. Dated August 15, 2007

Reply to Office Action of February 21, 2007

Attorney Docket No. 89188.0060 Customer No.: 26021

<u>proliferation of regulatory T cells</u>, wherein said blood cells are concentrated peripheral blood monoculear cells.

10. (Currently amended) The \underline{A} method of elaim-1 generating regulatory cells comprising:

incubating one or more proteins comprising a cytolethal distending toxin (cdt), a leukotoxin (ltx) and/or a heat shock protein with blood cells for a time sufficient to induce differentiation, selective enrichment, and/or promoting proliferation of regulatory T cells, wherein said regulatory T cells are Tr1.

11. (Original) A method of inducing differentiation and promoting proliferation of regulatory T cells comprising:

incubating peripheral blood mononuclear cells in the presence of at least three proteins, cytolethal distending toxin (cdt), leukotoxin (ltx) and a heat shock protein; and

selecting for Tr1 cells.

- (Original) The method of claim 11, wherein said proteins are secreted from a pathogenic organism.
- (Original) The method of claim 12, wherein said pathogenic organism is Actinobacillus actinomycetemcomitans.
- 14. (Original) The method of claim 11, wherein said proteins are introduced into said peripheral blood mononuclear cells in a purified form.

Amdt. Dated August 15, 2007

Reply to Office Action of February 21, 2007

- 15. (Original) The method of claim 11, wherein said proteins are introduced into said peripheral blood mononuclear cells as a crude extract.
- 16. (Original) The method of claim 11, wherein said proteins are introduced into said peripheral blood mononuclear cells by way of an expression vector.
- 17. (Original) A composition comprising an expression vector comprising a coding sequence for a cytolethal distending toxin (cdt), a leukotoxin (ltx) and a heat shock protein.
- 18. (Original) The expression vector of claim 17, further comprising a liposome.
- (Original) The expression vector of claim 18, for use as an immunosuppressant agent.

20-33. (Canceled)

- 34. (New) The method of claim 4, wherein said proteins are in a crude extract.
- 35. (New) The method of claim 4, wherein said proteins are in a purified form.